News & Updates
Filter by Specialty:
Potential therapeutic targets and repurposed drug identified for endometriosis
Researchers from the Chinese University of Hong Kong (CUHK) have identified two novel potential therapeutic targets and a drug approved for dry eyes that can be repurposed for treatment of endometriosis.
Potential therapeutic targets and repurposed drug identified for endometriosis
23 Jan 2025
Semaglutide extends benefits in obesity-associated knee OA
In individuals with obesity and moderate-to-severe pain due to knee osteoarthritis (OA), treatment with the GLP-1 RA* semaglutide led to significantly greater reductions in body weight and pain related to knee OA as opposed to placebo, findings from the STEP** 9 trial suggest.
Semaglutide extends benefits in obesity-associated knee OA
22 Jan 2025
Toripalimab plus chemo a good 1st-line CHOICE for advanced NSCLC
The prespecified final analysis of the phase III CHOICE-01 trial of toripalimab in combination with chemotherapy shows significant improvement in overall survival (OS) in treatment-naïve patients with advanced non-small-cell lung cancer (NSCLC) without EGFR/ALK driver mutations.
Toripalimab plus chemo a good 1st-line CHOICE for advanced NSCLC
22 Jan 2025
Could intermediate use of H1-antihistamines alongside ICIs extend OS in lung cancer?
A retrospective territory-wide cohort study by the Chinese University of Hong Kong (CUHK) reports an association between intermediate use of H1-antihistamines and longer overall survival (OS) in patients with lung cancer treated with immune checkpoint inhibitors (ICIs).
